Coiled Therapeutics PLC
30 September 2026
30 September 2026
Coiled Therapeutics plc
("Coiled Therapeutics" or the "Company")
Participation in The Small Cap Showcase
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF), the clinical-stage precision oncology company developing differentiated small molecule therapies for genetically defined cancers, announces that members of its executive management team will participate in The Small Cap Showcase on Thursday 1 October 2026 in New York City.
Dr Sotirios Stergiopoulos, Chairman and Stephen West, Non-Executive Director will present at 11:00 a.m. ET (4 p.m. BST), providing an overview of its business strategy, growth opportunities, recent developments and outlook. Management will also participate in one-on-one meetings with pre-qualified investors throughout the day.
A live webcast of the Company's presentation will be available at: https://www.webcaster5.com/Webcast/Page/3173/54585
The Small Cap Showcase is an investor-focused conference connecting executive management teams from approximately 12 micro- and small-cap public companies with institutional and other qualified investors. The event is designed to provide investors with meaningful access to differentiated small-cap investment opportunities through company presentations, one-on-one meetings and networking throughout the day.
For more information about The Small Cap Showcase, please visit www.smallcapshowcase.com.
-Ends-
Enquiries:
|
Coiled Therapeutics plc Sotirios Stergiopoulos (Chairman) Sridhar Vempati (CEO) |
Via Burson Buchanan |
|
SP Angel Corporate Finance LLP (Nominated Adviser & Joint Broker) David Hignell / Adam Cowl / Devik Mehta (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking) |
+44 (0)20 3470 0470 |
|
|
|
|
Shore Capital Stockbrokers Limited (Joint Broker) David Coaten / Sophie Collins |
+44 (0)20 7408 4090 |
|
CPS Capital Group Pty Ltd (Joint Broker) Jason Peterson / David Valentino |
+61 (0)8 9223 2222 |
|
|
|
|
Burson Buchanan (Public Relations) |
+44 (0)20 7466 5000 |
|
Henry Harrison Topham / Jamie Hooper / Toto Berger |
|
|
Harbor Access (US Investor Relations) |
+1 475 477 9404 |
|
Matt Kelly / Jonathan Paterson |
About Coiled Therapeutics plc
Coiled Therapeutics (AIM: COIL) (OTCQB: COTXF) is an AIM-listed, clinical-stage precision oncology company advancing first-in-class small molecule therapies targeting validated cancer dependencies. Its lead programme, AO-252, is a novel TACC3 inhibitor currently being evaluated in an ongoing Phase I clinical trial in the U.S. (ClinicalTrials.gov ID: NCT06136884). The Company's clinical development strategy focuses on generating evidence in selected tumour types, including ovarian and prostate cancer, to support potential pharmaceutical partnerships. Its broader pipeline includes a STAT-6 siRNA programme for immunology indications.
About AO-252
AO-252 is a first-in-class, orally administered, brain-penetrant small molecule designed to selectively inhibit Transforming Acidic Coiled-Coil containing protein 3 (TACC3). TACC3 has emerged as a validated cancer dependency across multiple aggressive solid tumours and is largely dispensable in normal adult cells, supporting the potential for a broad therapeutic window.
By disrupting TACC3-driven protein interactions, AO-252 induces mitotic and replication stress, impairs DNA damage repair and promotes cancer cell death. Its ability to cross the blood-brain barrier is a key differentiator, supporting its potential to treat both primary brain tumours and brain metastases.
The Company is currently enrolling patients in dose-escalation cohorts evaluating the new lipid-based softgel formulation of AO-252. Phase I/II dose-expansion cohorts in ovarian and prostate cancer are planned to follow once the optimal dose has been established.
For more information, please visit: www.coiledplc.com and follow us on LinkedIn.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.